Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration with 3M and the financial health of the company during the class period from January 5, 2023, to June 3, 2025 [1][3]. Company Overview - Neogen Corporation engages in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. - The company announced a merger with the Food Safety Division of 3M in December 2021, which was completed in September 2022 [2]. Allegations of the Lawsuit - The lawsuit alleges that Neogen's executives misrepresented the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3]. - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in revenue and EBITDA guidance for fiscal year 2025 [4]. - Following the announcement of its third quarter results on April 9, 2025, Neogen reported a loss of $11 million, a revenue decline of 3.4% to $221 million, and a significant drop in stock price by 28% [5]. - On June 4, 2025, Neogen projected a drop in EBITDA margin to the high teens from 22%, leading to a further stock price decline of over 17% [6]. Legal Process - Investors who purchased Neogen common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8][9].

Core Viewpoint - A class action lawsuit has been filed against Alto Neuroscience, Inc. for allegedly misleading investors regarding the effectiveness of its product ALTO-100 and its business prospects [1][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of purchasers of Alto common stock during the IPO on February 2, 2024, and securities purchased between February 2, 2024, and October 22, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by September 19, 2025, to represent other class members [3]. Group 2: Allegations Against Alto Neuroscience - Defendants allegedly made materially false and misleading statements about Alto's business and operations [5]. - Specific claims include that ALTO-100 was less effective in treating major depressive disorder than represented, leading to overstated clinical and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top for securities class action settlements and has recovered hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].

LOS ANGELES, July 22, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Neogen Corporation ("Neogen" or "the Company") (NASDAQ: NEOG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 5, 2023 and June 3, 2025, inclusive (the "Class Period"), are ...

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements (TSAs) with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=157197&from=3 CLASS PERIOD: Aug ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/capricor-loss-submission-form/?id=157205&from=3 CLASS PERIOD: October ...

LOS ANGELES, July 21, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 5, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT) securities between January 29, 2024 and March 11, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR IROBOT INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO ...

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth and Market Reaction - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary trade inventory loading at key retailers [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply on hand, which would negatively impact growth in Q3 2025 [3]. - Following this announcement, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, indicating that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A lawsuit has been filed against Reddit, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentations about user growth impacted by Google's AI technology [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Tamraz, Jr. v. Reddit, Inc., et al., No. 25-cv-05144 [2]. - Investors have until August 18, 2025, to request to be appointed to lead the case [2]. Group 2: Allegations Against Reddit - The complaint alleges that Reddit downplayed the negative impact of Google's AI on its user growth, which has been significant as users can find answers directly through Google without visiting Reddit [3][4]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Reddit securities [2]. Group 3: Stock Performance - Following a report on May 1, 2025, indicating a slowdown in daily active user growth, Reddit's stock price fell by $4.96, or over 4%, from $118.79 to $113.83 per share [5]. - On May 21, 2025, an analyst from Baird cut the stock price target due to concerns over Google's AI, leading to a further decline of $9.79, or over 9%, from $105.64 to $95.85 per share [6].